drugset / Trial / NCT06211790
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
Timeline
- Start
- 2024-01-16
- Primary completion
- 2025-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |